View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 15, 2021updated 12 Jul 2022 11:22am

Lilly releases full data from Phase II trial of donanemab in Alzheimer’s disease

Eli Lilly and Company has released detailed results of a Phase II TRAILBLAZER-ALZ study that was conducted to determine the efficacy of investigational antibody donanemab for treating Alzheimer's disease.

Eli Lilly and Company has released detailed results of a Phase II TRAILBLAZER-ALZ study that was conducted to determine the efficacy of investigational antibody donanemab for treating Alzheimer’s disease.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The detailed results were presented at the 15th International Conference on Alzheimer’s & Parkinson Diseases 2021 (AD/PD 2021) that was held virtually last week, as well as published in the New England Journal of Medicine (NEJM).

The move comes around two months after Lilly reported positive data from the trial.

The randomised, placebo-controlled, double-blind, multi-centre study aimed to assess the safety, tolerability and efficacy of donanemab in patients with early symptomatic Alzheimer’s disease.

It enrolled 272 patients selected on cognitive assessments, along with amyloid plaque imaging and tau staging by PET imaging.

According to the trial data, donanemab achieved its primary endpoint slowing decline by 32% versus placebo on the integrated Alzheimer’s Disease Rating Scale (iADRS) at 76 weeks compared to baseline.

The antibody also slowed cognitive and functional decline, with ranges between 20% to 40% in all secondary endpoints with nominal statistical significance.

Lilly Research Laboratories president Daniel Skovronsky said: “This is the first late-stage study in Alzheimer’s disease to meet its primary endpoint at the primary analysis.

“Donanemab has the potential to become a very important treatment for Alzheimer’s disease. We were pleased to see not only slowing of cognitive and functional decline, but also very substantial clearance of amyloid plaques and slowing of spread of tau pathology.

“The constellation of clinical and biomarker results indicates the potential for long-term disease modification. We are grateful to the patients, caregivers, and investigators who participated in this landmark study.”

TRAILBLAZER-ALZ 2 is currently underway, which is also testing the safety, tolerability and efficacy of donanemab in a randomised, placebo-controlled, double-blind, multi-centre study.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena